CYDX (Cyduct Diagnostics) Change In Receivables: $0.00 Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cyduct Diagnostics Change In Receivables?

Cyduct Diagnostics CYDX -19.35% Change In Receivables is $0.00 Mil as of . 20.

Cyduct Diagnostics's change in receivables for the quarter that ended in . 20 was $0.00 Mil. It means Cyduct Diagnostics's Accounts Receivable stayed the same from . 20 to . 20 .

Cyduct Diagnostics's change in receivables for the fiscal year that ended in . 20 was $0.00 Mil. It means Cyduct Diagnostics's Accounts Receivable stayed the same from . 20 to . 20 .

Cyduct Diagnostics's Accounts Receivable for the quarter that ended in . 20 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cyduct Diagnostics's liquidation value for the three months ended in . 20 was $0.00 Mil.

Cyduct Diagnostics  (OTCPK:CYDX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cyduct Diagnostics's Days Sales Outstanding for the quarter that ended in . 20 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=/*91
=

2. In Ben Graham's calculation of liquidation value, Cyduct Diagnostics's accounts receivable are only considered to be worth 75% of book value:

Cyduct Diagnostics's liquidation value for the quarter that ended in . 20 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=-+0.75 * +0.5 *
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyduct Diagnostics Change In Receivables Related Terms

Cyduct Diagnostics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Cyduct Diagnostics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyduct Diagnostics Change In Receivables Chart

Cyduct Diagnostics Annual Data
Trend
Change In Receivables

Cyduct Diagnostics Quarterly Data
Change In Receivables

Cyduct Diagnostics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in . 20 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.00 Mil mean?
Cyduct Diagnostics (CYDX) has a Change In Receivables of $0.00 Mil as of . 20. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Cyduct Diagnostics and its competitors.
Is Cyduct Diagnostics' Change In Receivables too high?
Cyduct Diagnostics' current Change In Receivables is $0.00 Mil.
How does Cyduct Diagnostics' Change In Receivables compare to SECI and QTXB?
Cyduct Diagnostics' Change In Receivables of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Cyduct Diagnostics and its competitors. Cyduct Diagnostics's current Change In Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyduct Diagnostics stock overvalued right now?
Cyduct Diagnostics (CYDX) has a current Change In Receivables of $0.00 Mil. The current Change In Receivables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Cyduct Diagnostics (CYDX), the current Change In Receivables is $0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cyduct Diagnostics Business Description

Address 1698 Post Road East, Suite 1A, Westport, CT, USA, 06880
Cyduct Diagnostics Inc is a clinical-stage diagnostic company. It focuses on creating and enhancing a portfolio of technologies and assets based on the early assessment and detection of Breast Cancer. Its technology platform of MammoView devices is a single-use, high-margin product that assesses, screens, detects, monitors, and facilitates the treatment of identifiable changes that distinguish variations in breast health. The company markets these products under its Solos Endoscopy brand, along with a line of branded surgical instruments, manufactured by third parties to its design specifications, mainly endoscopes and hand-held surgical instruments for the minimally invasive surgery market.